Is VRTX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

2,578 people get VRTX articles and Market Currents by email alert.

Get email alerts on VRTX »

HEADLINES:

Vertex Calls for Redemption of $400 Million in Convertible Senior Subordinated Notes Due 2015

Business Wire (Fri, 8:30AM)
This Stock Deserved Its Sudden Upswing
Northwest Trader • Mon, May 13 • 11 Comments
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

Business Wire (May 9, 2013)
Vertex Debt Conversion Is Not Bad For Shareholders
Northwest Trader • Thu, May 9 • 9 Comments
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Life Sciences Report • Fri, May 3 • 3 Comments
Vertex Pharmaceuticals Beats Analyst Expectations, Yet Insiders Continue To Sell More Shares
Edward Vranic • Fri, May 3 • 2 Comments
Why BioMarin, Catalyst Pharmaceutical Partners And Vertex Are Expected To Outperform
Tom Welch • Wed, May 1 • 2 Comments
Vertex Pharmaceuticals Incorporated Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, Apr 30 • 2 Comments
Vertex Reports First Quarter 2013 Financial Results and Reviews Recent Progress in Development Programs for Cystic Fibrosis and Hepatitis C

Business Wire (Apr 30, 2013)
NewLink Genetics: Looking To Join The Industry's Largest Movers
A John Hodge • Mon, Apr 29 • 3 Comments
Vertex Announces New Data that Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment Among People with Genotype 1 Hepatitis C Who Have the IL28B CC Genotype

Business Wire (Apr 24, 2013)
Cramer's Lightning Round - EMC Is Controversial (4/23/13)
SA Editor Miriam Metzinger • Wed, Apr 24 • 1 Comment
Vertex Spikes On Phase II Data, Then The CFO Sells His Shares
Edward Vranic • Wed, Apr 24 • 10 Comments
ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection

Business Wire (Apr 23, 2013)
Catalyst Deserves The Attention
Veziris Ventures • Tue, Apr 23 • 4 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Mon, Apr 22 • 1 Comment
Biotech Stocks Get A Turbo Boost From Vertex
Rod Raynovich • Sat, Apr 20 • 3 Comments
Vertex Pharmaceuticals' CEO Hosts Phase II Results for VX-661 Conference (Transcript)
Fri, Apr 19 • 5 Comments
Treatment with VX-661 and Ivacaftor in a Phase 2 Study Resulted in Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation

Business Wire (Apr 18, 2013)
Vertex Enters Agreement with Bristol-Myers Squibb for Phase 2 All-Oral Studies of VX-135 in Combination with Daclatasvir for the Treatment of Hepatitis C

Business Wire (Apr 5, 2013)

To learn more about Seeking Alpha Pro, click here.

This Stock Deserved Its Sudden Upswing
Northwest Trader • Mon, May 13 • 11 Comments
Vertex Debt Conversion Is Not Bad For Shareholders
Northwest Trader • Thu, May 9 • 9 Comments
Vertex Pharmaceuticals Beats Analyst Expectations, Yet Insiders Continue To Sell More Shares
Edward Vranic • Fri, May 3 • 2 Comments
Vertex Spikes On Phase II Data, Then The CFO Sells His Shares
Edward Vranic • Wed, Apr 24 • 10 Comments
Biotech Stocks Get A Turbo Boost From Vertex
Rod Raynovich • Sat, Apr 20 • 3 Comments
Vertex: The Sun Sets On Incivek, Rises On Its CF Franchise
PropThink • Thu, Mar 14
Vertex's True Value Overlooked
WM Analyst • Thu, Jan 31 • 1 Comment
Why You Should Sell Vertex
Rx Stocks • Mon, Jan 21 • 16 Comments
Kalydeco Approval In Canada More Important To Patients Than To Vertex
PropThink • Mon, Dec 3, 2012 • 1 Comment
Pessimism On Vertex Pharmaceuticals Increases, Erasing Previous Gains
Brian L. Wilson • Fri, Nov 16, 2012 • 5 Comments
Vertex Gets Uneasy On Mixed Clinical Trial Results
Brian L. Wilson • Fri, Oct 12, 2012 • 6 Comments
Vertex's Cystic Fibrosis Pipeline Offers Sales Upside
Todd Campbell • Wed, Aug 1, 2012 • 3 Comments
Why You Should Be Bullish On Vertex Now
Ry Frank • Mon, Jul 9, 2012 • 3 Comments
Vertex's Data Bungle Offers Entry Point
Jessica King Holden • Tue, May 29, 2012 • 1 Comment
Vertex's Cystic Fibrosis Drug Impresses Investors
The Burrill Report • Sun, May 13, 2012
Vertex Cystic Fibrosis Data Defies Market Drop
Todd Campbell • Wed, May 9, 2012 • 5 Comments
Vertex: Well-Equipped To Own The Future
Prohost Biotech • Tue, May 8, 2012 • 4 Comments
5 Biotech Stocks With Massive Upside Potential In 2013
Cris Frangold • Mon, May 7, 2012 • 5 Comments
Vertex: This Patent King Is The Stock Du Jour
Dividend Kings • Mon, May 7, 2012 • 1 Comment
Finding Opportunity In Small Biotech Companies
Insider Monkey • Thu, Apr 26, 2012 • 4 Comments

Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Life Sciences Report • Fri, May 3 • 3 Comments
Why BioMarin, Catalyst Pharmaceutical Partners And Vertex Are Expected To Outperform
Tom Welch • Wed, May 1 • 2 Comments
NewLink Genetics: Looking To Join The Industry's Largest Movers
A John Hodge • Mon, Apr 29 • 3 Comments
Cramer's Lightning Round - EMC Is Controversial (4/23/13)
SA Editor Miriam Metzinger • Wed, Apr 24 • 1 Comment
Catalyst Deserves The Attention
Veziris Ventures • Tue, Apr 23 • 4 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Mon, Apr 22 • 1 Comment
Cramer's Mad Money - Is Apple Bottoming? (4/2/13)
SA Editor Miriam Metzinger • Wed, Apr 3 • 12 Comments
3 Reasons To Buy This Leading Drug Stock Right Now
StreetAuthority • Fri, Mar 22 • 2 Comments
The Stem Cell Revolution Can Jump Start Your Portfolio: Jason Kolbert
Life Sciences Report • Fri, Mar 15 • 16 Comments
Achillion: A Tiny Biopharmaceutical Stock With Tremendous Potential
Regarded Solutions • Wed, Mar 13 • 63 Comments
Growing Pains: Pacira Stretched Very Thin Following Exparel Launch
Richard Pearson • Wed, Mar 13 • 6 Comments
VIX - Options Volatility And Market Sonar: Wednesday Recap
Erick McKitterick • Wed, Jan 30 • 15 Comments
UDR Is Trading At A Discount With A Strong Case For Growth
Stephen Ryan • Wed, Jan 16
Will 2013 Be A Better Year For Zalicus?
C.R. Jackson • Thu, Jan 10 • 2 Comments
Achillion: Poised For Growth And Now Is The Time To Buy
Regarded Solutions • Wed, Jan 2 • 5 Comments
Danger Zone: iShares S&P MidCap 400 Growth Index Fund (IJK)
David Trainer • Mon, Dec 31, 2012 • 3 Comments
Lessons From The Liver Meeting: Sagient's John Tucker Names Companies That Could Reignite The Hepatitis C Industry
Life Sciences Report • Fri, Nov 30, 2012 • 3 Comments
Is Gilead Sciences Still A Good Buy?
C.R. Jackson • Wed, Nov 28, 2012 • 1 Comment
The 12 Most Oversold Mid-Caps
Alan Brochstein • Mon, Nov 26, 2012 • 3 Comments
New Second Generation Combination Therapy For HCV - First Or Best In The Market - Part 2
LifeSci Advisors • Tue, Nov 20, 2012

Vertex Pharmaceuticals Incorporated Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, Apr 30 • 2 Comments
Vertex Pharmaceuticals' CEO Hosts Phase II Results for VX-661 Conference (Transcript)
Fri, Apr 19 • 5 Comments
Vertex Pharmaceuticals' Management Presents at Barclays Global Healthcare Conference (Transcript)
Tue, Mar 12
Vertex Pharmaceuticals Incorporated - Special Call
Wed, Feb 27
Vertex Pharmaceuticals Incorporated CEO discusses Q4 2012 Results - Earnings Call Transcript
Tue, Jan 29
Vertex Pharmaceuticals Incorporated Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 1, 2012
Vertex Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Jul 31, 2012
Vertex's Management Present at Deutsche Bank Securities, Inc. 37th Annual Health Care Conference (Transcript)
Fri, May 11, 2012
Vertex Pharmaceuticals Incorporated's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Thu, Apr 26, 2012
Vertex Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Thu, Feb 2, 2012
Vertex Pharmaceuticals' CEO Presents at JPMorgan Global Healthcare Conference (Transcript)
Mon, Jan 9, 2012
Vertex Pharmaceuticals at Credit Suisse 2011 Healthcare Conference Call Transcript
Wed, Nov 9, 2011 • 1 Comment
Vertex Pharmaceuticals Incorporated's CEO Discusses Q3 2011 Results - Earnings Call Transcript
Fri, Oct 28, 2011
Vertex Pharmaceuticals Incorporated's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Fri, Jul 29, 2011
Vertex Pharmaceuticals Inc. Q4 2009 Earnings Call Transcript
Fri, Feb 5, 2010
Vertex Pharmaceuticals Q3 2009 Earnings Call Transcript
Mon, Oct 26, 2009
Vertex Pharmaceuticals Incorporated, Q4 2008 Earnings Call Transcript
Mon, Feb 9, 2009 • 1 Comment
Vertex Pharmaceuticals Incorporated Q3 2008 Earnings Call Transcript
Mon, Oct 27, 2008
Vertex Pharmaceuticals Incorporated. Q2 2008 Earnings Call Transcript
Thu, Jul 31, 2008
Vertex Pharmaceuticals Q1 2008 Earnings Call Transcript
Mon, Apr 21, 2008

Vertex Calls for Redemption of $400 Million in Convertible Senior Subordinated Notes Due 2015

Business Wire (Fri, 8:30AM)
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

Business Wire (May 9, 2013)
Vertex Reports First Quarter 2013 Financial Results and Reviews Recent Progress in Development Programs for Cystic Fibrosis and Hepatitis C

Business Wire (Apr 30, 2013)
Top Undervalued Pharma Stock: Analyst

at CNBC.com (Apr 29, 2013)
Vertex Announces New Data that Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment Among People with Genotype 1 Hepatitis C Who Have the IL28B CC Genotype

Business Wire (Apr 24, 2013)
ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection

Business Wire (Apr 23, 2013)
Stocks End Up, But Log Worst Weekly Drop in 2013

at CNBC.com (Apr 19, 2013)
Movers & Shakers: Friday’s movers: IBM biggest loser in S&P 500

at MarketWatch.com (Apr 19, 2013)
Futures Pare Gains on Earnings; GE, MCD Lower

at CNBC.com (Apr 19, 2013)
Stocks to Watch: Stocks to watch: GE, McDonald’s, IBM

at MarketWatch.com (Apr 19, 2013)
Early Movers: GE, MDLZ, DELL & More

at CNBC.com (Apr 19, 2013)
After-Hours Buzz: GOOG, IBM, MSFT & More

at CNBC.com (Apr 18, 2013)
Treatment with VX-661 and Ivacaftor in a Phase 2 Study Resulted in Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation

Business Wire (Apr 18, 2013)
Vertex Enters Agreement with Bristol-Myers Squibb for Phase 2 All-Oral Studies of VX-135 in Combination with Daclatasvir for the Treatment of Hepatitis C

Business Wire (Apr 5, 2013)
Cramer: 3 Stocks on the Speculative Side

at CNBC.com (Apr 2, 2013)
Vertex to Report First Quarter 2013 Financial Results on Tuesday, April 30

Business Wire (Apr 1, 2013)
Mark Hulbert: Get out of junk stocks now

at MarketWatch.com (Mar 22, 2013)
VX-787 Showed Significant Antiviral Activity and Reduced the Severity and Duration of Influenza Symptoms in Phase 2 Challenge Study

Business Wire (Mar 4, 2013)
Vertex Announces Webcasts of its Presentations at Two Investor Conferences

Business Wire (Feb 27, 2013)
Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for the Treatment of People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation

Business Wire (Feb 26, 2013)

VRTX vs. ETF Alternatives

Company Description

We are in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Telaprevir, our lead drug candidate, is an oral hepatitis C protease inhibitor and one of the most advanced of a new class of antiviral treatments in clinical... More

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 1:49 PM Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3%, ALXN -4.2%, VRTX -2.3%, CELG -4.5%, ARRY -2.2%, AMGN -1.4%. 1 Comment [Healthcare, On the Move]
Tuesday, April 30, 4:54 PM More on Vertex Pharmaceuticals (VRTX): Q1 beats on both EPS and revenue, but net profit swung to a loss on a 25% drop in total sales as fewer patients initiated treatment - leading to a 42% drop in Incivek revenue - and its bottom line was hit by a write down tied to its hepatitis C program. The drug devoeloper has now reported four straight quarters of losses amid slumping sales of Incivek as patients and doctors await new therapies from other drug developers. Shares +1% AH. Comment! [Healthcare, Earnings, On the Move]
Tuesday, April 30, 4:13 PM Vertex Pharmaceuticals (VRTX): Q1 EPS of $0.03 beats by $0.21. Revenue of $328M (-25% Y/Y) beats by $20M. (PR). Shares +0.3% AH. Comment! [Earnings, Healthcare, Breaking News]
Saturday, April 27, 10:53 PM Combining Gilead's (GILD) sofosbuvir and Bristol-Myers Squibb's (BMY) daclatasvir cures 100% of hepatitis C patients in 12 weeks (including those who failed treatment with Vertex's (VRTX) Incivek and Merck's (MRK) Victrelis) and looks to be a better treatment option for those with genotype 3 than a combo of sofosbuvir and another GILD drug ledipasvir. The problem: "GILD very clearly wants to develop in-house," one clinician tells Bloomberg. (See also: ABBV's HCV treatment successful; VRTX teams with BMY on HCV trial) 5 Comments [Healthcare]
Wednesday, April 24, 10:03 AM Vertex Pharmaceuticals (VRTX -3.4%) slips after SA contributor Edward Vranic highlights a recent insider transaction by the company's CFO. Form 4 filings seem to show a large block of shares transacted on April 19, the day the stock rose more than 60% on positive Phase 2 trial data (I, II, III). Earlier this week, S&P equity research raised their price target to $100 from $60, adding to a slew of positive analyst coverage the stock has received over the past week. Cramer's take: "Don't sell your Vertex, [it] has a breakout drug right now." 1 Comment [Healthcare, On the Move]
Friday, April 19, 1:09 PM Midday top 10 gainers: VRTX +60%. NETE +33%. RH +21%. MCOX +18%. OSTK +17%. HWAY +17%. NVDQ +16%. ANAC +12%. LIVE +11%. CMG +10%.
Midday top 10 losers: ACTG -25%. VIMC -15%. PRGX -14%. AIRM -14%. NSIT -12%. CNIT -11%. RMBS -10%. CRME -10%. DIT -9%. OSH -9%. 1 Comment [On the Move]
Friday, April 19, 9:17 AM Vertex Pharmaceuticals (VRTX), which probably didn't need any more catalysts, gets a lift from upgrades at both Canaccord (Buy from Hold) and Goldman (Neutral from Sell). Canaccord says "the CF corrector discovery platform" has been validated and the "likelihood for trial success and uptake" has increased. Goldman admits to being "completely wrong" about the prospects for VRTX's CF combo platform. Price targets: $96 at Canaccord and $86 at Goldman. Shares +62% premarket. Comment! [Healthcare, On the Move]
Friday, April 19, 9:15 AM Premarket gainers: VRTX +62%. IMOS +17%. CE +9%.
Losers: AIRM -18%. Comment! [On the Move]
Friday, April 19, 7:41 AM Vertex Pharmaceuticals (VRTX) now up 57% premarket after reporting positive test results last night. Previously bullish Deutsche raises its price target to $100 from $75, thinking the company could earn $10/share in 2015 and putting the stock's fair value as high as $150. Goldman's on the case, upgrading to Hold from Sell and raising its price target to $86 from $38. Comment! [Healthcare, On the Move]
Thursday, April 18, 5:49 PM Wells Fargo's Brian Abrahams likes the news on Vertex (VRTX), saying it cleanly validates the efficacy of it's corrector/potentiator approach, and meaningfully increases the likelihood of success in its '809/Kalydeco Phase III program, and at worst gives VRTX a high probability shot for '661/Kalydeco to capture this multi-billion dollar opportunity. As such, Abrahams sees significant upside potential from the news. 1 Comment [Healthcare]
Thursday, April 18, 4:20 PM Vertex Pharmaceuticals (VRTX) jumps 49% after the bell as the company says data from a Phase 2 study of a combined corrector/potentiator treatment for cystic fibrosis patients with two copies of the F508del gene mutation showed "statistically significant, dose-dependent, improvements in lung function. Comment! [Healthcare, On the Move]
Wednesday, April 10, 12:53 PM Vertex Pharmaceuticals (VRTX +4%) posts a gain this morning after Chardan Capital Markets starts the shares with a Buy rating and a price target of $80 a share. The firm is taking a much more aggressive stance than Canaccord yesterday, who initiated the shares with a Hold and a modest $55 price target. Comment! [Healthcare, On the Move]
Monday, April 8, 12:31 PM Vertex Pharmaceuticals (VRTX -3.6%) slips today on a tepid start from Canaccord with a Hold rating and modest $55 price target. The firm says its key value driver is its VX-809/Kalydeco combination therapy for cystic fibrosis, for which Phase 3 data is due out in 2014, but the the near-term focus is on top-line Phase 2 data for VX-661/Kalydeco, which is due out in Q2 and may show only modest improvements. Comment! [Healthcare, On the Move]
Friday, April 5, 10:35 AM Vertex Pharmaceuticals (VRTX +0.1%) bucks a weak tape this morning after saying it's entered into a non-exclusive agreement with Bristol-Myers Squibb (BMY -0.3%) to conduct Phase 2 studies of VRTX's VX-135 in combination with BMY's daclatasvir for the treatment of hepatitis C. As part of the agreement, VRTX will also conduct two Phase 2 studies of the combination, including an initial study in treatment-naive people with genotype 1 HCV infection. The second study is planned for Q2. Comment! [Healthcare]
Monday, March 4, 9:04 AM Vertex Pharmaceuticals' (VRTX) VX-787 flu treatment achieves "statistically significant improvements in viral and clinical measurements of infection" in a Phase II trial and meets its primary endpoint. VX-787 is a new class of medicine that is "designed to directly inhibit replication of the virus." VX-787 was also "generally well-tolerated, with no adverse events leading to discontinuation." (PR) Comment! [Healthcare]
Friday, February 1, 2:11 PM Vertex Pharmaceuticals (VRTX +1.4%) gains after announcing earlier that the Health Service Executive in the Republic of Ireland will fund Kalydeco. The drug is the first to treat the underlying cause of cystic fibrosis for people ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene, and helps the defective protein function more normally. Comment! [Healthcare, On the Move, Global & FX]

smokeyRose
My Hot picks...That are working Nicely For me...$EXR $HTZ $THRX $XDSL ones I Don't own But would like to $ABBV $VRTX Have a Nice Day! :)
Apr 26, 11:18 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
Fuinhaz Setups for April 19 2013 | $ASML $GOLD $GOOG $MDLZ $MSFT $PSEC $VOD $VRTX $VVUS $ZNGA | SharePlanner http://bit.ly/11nYSVZ
Apr 19, 9:20 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
New Upgrades (4/12/13): $MGIC, $MN, $MYGN, $NMM, $NSC, $NVDA, $SCVL, $TRIP, $TZOO, $VAR, $VRTX, $WCRX, $WEN, $WYN
Apr 15, 9:01 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Derek Chipman
VRTX presents attractive options
11/10/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

nsahbti
VRTX : Is this horse limping? whats next?
10/25/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joe Springer
Insider's showing their hands: http://bit.ly/TuYnnJ $MNKD $ARIA $VRTX $OREX $FOLD $ZLTQ $ISIS
10/17/12
Reply (4)

• !Report Abuse
View all 4 replies
mark woods: Did you say FOLD had strong insider selling or buying?
10/18/12
• !Report Abuse
Joe Springer: Hey Mark - Buying http://bit.ly/U9xCdG
10/18/12
• !Report Abuse
Add a reply...

140 characters

ZetaKap
4 Profitable Healthcare Stocks Forecasted To Grow EPS By At Least 25% http://bit.ly/UhMyaw $ALXN $ELN $FRX $VRTX @ZetaKap
10/4/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Wall Street Transcript
Merck ($MRK), Vertex Pharmaceuticals ($VRTX) and Gilead Sciences ($GILD) Trailblaze Hepatitis C Therapies - http://su.pr/2L7YFf
9/21/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
3 Liquid And Profitable Biotech Stocks http://bit.ly/OLfxfL $SIGA $SPPI $VRTX @ZetaKap
8/6/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
5 Profitable Large Caps Flush With Cash http://bit.ly/ROWp0M $COH $MNST $SCCO $SQM $VRTX @ZetaKap
8/6/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Joe Springer
Insider's showing their hands: http://bit.ly/TuYnnJ $MNKD $ARIA $VRTX $OREX $FOLD $ZLTQ $ISIS
10/17/12
Reply (4)

• !Report Abuse
View all 4 replies
mark woods: Did you say FOLD had strong insider selling or buying?
10/18/12
• !Report Abuse
Joe Springer: Hey Mark - Buying http://bit.ly/U9xCdG
10/18/12
• !Report Abuse
Add a reply...

140 characters

Randy Lacen
Pharma Stocks to choose from: QCOR, SPPI, LLY, CAH, ABT, CBST, AKRX, VRTX, ANIK, USNA, CTRX
6/27/12
Reply (1)

• !Report Abuse
View all 1 replies
vireoman: Okee-doke
6/27/12
• !Report Abuse
Add a reply...

140 characters

MitchSand
KINS, UG, CAKE, VRTX, SWX, FL, CHD are all going up
6/5/12
Reply (4)

• !Report Abuse
View all 4 replies
realornot: I highly recommend buying the entire S&P 500.
6/5/12
• !Report Abuse
MitchSand: no
6/6/12
• !Report Abuse
Add a reply...

140 characters

wmuraga
Any views on VRTX?, due for a pull back?.
5/7/12
Reply (13)

• !Report Abuse
View all 13 replies
freefdawatchlist: VRTX is up 10% premarket
5/9/12
• !Report Abuse
wmuraga: Why is SPPI's short interest so high?. Not sure this is a good time to open a position....
5/10/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Vertex Pharmaceuticals (VRTX), Zillow (Z), LinkedIn (LNKD), Caseys Stores (CASY), & Trimble Navigation (TRMB) rose Tuesday on unusual volume
5/8/12
Reply (4)

• !Report Abuse
View all 4 replies
Brandon Gibbs: No it jumped on positive phase II results, Cramer just said he believes there's still a lot of upside. Talked about their biz a little
5/8/12
• !Report Abuse
mitrado: VRTX went from 37$ to 38$ after Kalydeco's FDA approval and from 38$ to 64$ after a 48 patient phase II study. Sold it. This seems too fishy
5/9/12
• !Report Abuse
Add a reply...

140 characters

LT
Bought VRTX this morning, nice gain so far, looking at BCRX next for hep C play.
2/27/12
Reply (1)

• !Report Abuse
View all 1 replies
mitrado: Still holding $VRTX!? I've sold at 37.5$ ... watched it fly up to 41$ ... and I've just got back in at 36.45$.
4/13/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
Check out upcoming Fda approval Dates http://bit.ly/H6kqQR $ARNA, $RGEN, $XNPT, $SLXP, $GILD, $ALXA, $PLX,$VVUS, $AMGN,$FURX,$CTIC,$VRTX
4/1/12
Reply (3)

• !Report Abuse
View all 3 replies
freefdawatchlist: don't buy more, because if fda delay it by 3 month, the stock may drop. Check out other stock which haven't rallied up till now.
4/1/12
• !Report Abuse
phemale60: VVUS's Avanafil up for FDA approval late April also. Any info about it? I appreciate your insight!
4/1/12
• !Report Abuse
Add a reply...

140 characters

mitrado
Sold VRTX at 37.5 ... Don't care if the earnings are in 2 days. Bought at 30. I'm quite satisfied already! :-D
1/31/12
Reply (3)

• !Report Abuse
View all 3 replies
Oceanstats: Never hate profit.
1/31/12
• !Report Abuse
mitrado: Looks like I haven't lost that much... :-/ Stupid idiots at Goldman Sachs just decided to screw Vertex again.
2/3/12
• !Report Abuse
Add a reply...

140 characters

VRTX Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated